Nencini C, Giorgi G, Micheli L
Our internal protocol is being monitored by our clinical team, and we will transition to patient-facing availability only when we are satisfied with our own observations and with the emerging evidence base
A single-peptide BPC-157 protocol starts at a 1-cycle level with 2- and 3-cycle options that bring the per-cycle cost down
Its anti-inflammatory properties, ability to promote tissue repair, and enhancement of blood flow make it a powerful tool in joint pain management
Reducing Peptide Degradation Risks What drives it: heat, light, oxygen, and time
Clinicians prescribing BPC-157 should document the following in the medical record: the off-label nature of the prescription, the absence of human clinical trial data, the FDA's position on compounded BPC-157, the patient's prior treatment history with approved therapies, and the patient's written informed consent